Health News Releases

  • Today May 30
May 29, 15:07
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Dru
May 29, 14:36
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clini
May 26, 11:55
Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023
Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO)
May 25, 11:30
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capab
May 24, 17:10
Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women
Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages. The
May 24, 15:30
ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
Siemens Ltd. Seoul’s ‘The NANUM’ volunteer corps is serving Chicken Soup with Oriental Medicines to
May 19, 13:26
Siemens Korea conducts volunteer activities for local senior citizens in celebration of Family Month
A global powerhouse in electrical engineering and electronics, Siemens Korea (Siemens Ltd. Seoul·SLS) announced that the company served meals to the elderly in celebration of Family Month, on May 19.
May 18, 13:50
Alliance Pharma and Drug Development Solutions Are Now Resolian
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022),
May 17, 16:52
Next&Bio Signs MOU with Cancer Science Institute of Singapore for Organoid Collaboration
Next&Bio Inc. (Co-CEO: HyunSook Lee, Ji-Hun Yang), a company that has developed an organoid-based precision medicine drug discovery and development platform, has signed a memorandum of understanding (
May 17, 10:55
Parse Biosciences Expands Global Access to Israel
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend
May 17, 09:40
UK’s Nurse Margaret Wins the Coveted Aster Guardians Global Nursing Award 2023
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winne
May 16, 17:20
Carbios Recognized as a Flagship Start-up in French Green Innovation at the Choose France Summit
Regulatory News: Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, has been s
May 16, 15:50
AOP Health congratulates FROM on its great scientific work in the field of myeloproliferative neoplasms
Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) announced the publication of the latest results from the LOW-PV trial in the NEJM Evidence. The findings support a paradigm shift in the tr
May 15, 10:02
Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus. lactis strain Plasma[1](L.lactis Plasma, a postbiotic), researched and developed by
May 14, 10:15
AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera
AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger
May 12, 14:45
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its
May 12, 09:35
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it will provide its inactivated COVID-19 vaccine, CoronaVac®
May 11, 13:29
Oncocross Completes Phase 1 Global Clinical Trial of OC514, Treatment for Sarcopenia
Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular disease
May 10, 17:22
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The
May 10, 15:40
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerab
May 10, 14:50
Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-10
May 10, 11:30
Kenvue Announces Closing of Initial Public Offering
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its co
May 10, 10:15
Four Analyses of Data for REBYOTA™ (fecal microbiota, live - jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live - jslm) a first-in-class single-
May 09, 16:55
Amicogen and Lysando: Novel Approach for the Treatment of Mastitis in Dairy Cows
Amicogen, a leading biotech company specializing in industrial enzyme production and drug development, has partnered with Lysando, an innovative biotech company with expertise in the development of an
May 09, 10:40
Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™
Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicin
25 per page50 per page75 per page100 per page